PSY80 The Importance Of Fact Over Opinion In Choice Of Conditions To Be Recommended For Newborn Screening (Nbs)  by Rittenhouse, B
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A237
primary target for drug-seeking patients, this pilot study was conducted to validate 
a survey instrument designed to assess emergency physicians (EPs) intention to 
use the recently available Texas PMP. Methods: A cross-sectional survey of EPs 
was conducted at a statewide emergency medicine conference. A 34-item ques-
tionnaire, based on the Technology Acceptance Model (TAM), was developed to 
assess EPs intention to use the Texas PMP. Items related to technology acceptance 
(perceived ease of use, perceived usefulness, attitude, and intention) were assessed 
using 5-point Likert scale responses (1= strongly disagree to 5= strongly agree). The 
survey expanded on a previous exploratory survey of EPs. Correlation analyses 
were used to validate the survey instrument scales. Results: Of the 45 respond-
ents, most were male (68.9%), attending EPs (57.8%), with 10.8±11.1 years in emer-
gency medicine, from a community hospital setting (55.6%), and were users of the 
Texas PMP (51.2%). Among those who were not registered, 39.2% reported lack of 
awareness as the primary reason for not being registered. Standardized Cronbach’s 
alphas for the constructs of perceived ease of use, perceived usefulness, attitude, 
and intention for PMP users were 0.88, 0.90, 0.74, and 0.84, respectively; and 0.77, 
0.87, 0.84, and 0.74, respectively for PMP non-users. ConClusions: Considering 
the ED as a source of diversion, it is important to understand EPs utilization of 
PMPs. EPs use of PMPs may help to mitigate the economic burden associated with 
the non-medical use of prescription opioids, while improving patient outcomes. 
Future studies using this survey instrument are needed to further assess the 
predictive utility.
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objeCtives: To evaluate the sensitivity and specificity of opioid overutilization 
quality measures based on the Centers for Medicare and Medicaid Services (CMS) 
Controlled Substance Overutilization Monitoring System (OMS) using proxy indica-
tors of potential overutilization. Methods: Based on the CMS measure (propor-
tion of patients with opioid prescriptions from ≥ 4 prescribers and ≥ 4 pharmacies 
among patients with ≥ 2 opioid prescriptions), claims from the 2012 IMS LRx data-
base were used to evaluate the metric at different prescriber and pharmacy thresh-
olds. Cash payment of ≥ 1 opioid prescription was used as a proxy for potential 
overutilization and set as the dependent variable in logistic regression models to 
generate separate receiver operating characteristic (ROC) curves for thresholds 
of 2-8 prescribers and 2-8 pharmacies. Optimal cutpoints for number of physi-
cians and pharmacies were selected as the value on the curve with the shortest 
distance to perfect prediction. Sensitivity, specificity and positive predictive value 
(PPV) for every combination were calculated. As a sensitivity analysis, the process 
was repeated using ≥ 1 opioid-abuse related diagnosis as a proxy for potential 
overutilization. Results: Of the 1,213,909 qualified patients, 5.9% met the CMS 
criteria for overutilization, while 13.8% met the alternative ROC optimal criteria 
(≥ 4 prescribers and ≥ 3 pharmacies). Defining cash payment patients (12.3% of 
total) as overutilizers, the CMS definition had sensitivity (15.0%), specificity (95.3%) 
and PPV (31.0%) The ROC alternative had sensitivity (28.0%), specificity (88.2%) and 
PPV (24.9%). For patients with opioid abuse-related claims defined as overutiliz-
ers (2.6% of total), the CMS criteria had sensitivity (16.1%), specificity (94.3%) and 
PPV (7.0%). The ROC alternative had sensitivity (28.5%), specificity (86.6%) and 
PPV (5.3%). ConClusions: Using two proxies for opioid overutilization, analy-
sis of ROC curves suggested optimal criteria similar to the CMS criteria. Quality 
organizations can use the range of results and their preferences for sensitivity 
and specificity tradeoffs to develop needed quality measures.
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objeCtives: In 2006, the American College of Medical Genetics (ACMG) recom-
mended expanding NBS. Recommendations relied largely on a stakeholder survey 
on 19 attributes of different rare conditions under consideration. The percentage of 
respondents agreeing to an attribute’s presence determined its score. This research 
examines one particular attribute and asks how the recommendation of included 
conditions changes with the substitution of scoring based on the actual facts for that 
based on surveyed opinion. Methods: The original report indicated each condi-
tion’s scores for survey questions. Unlike some questions, that of whether multiplex 
technologies (allowing multiple conditions to be screened with a single test) were 
available, had a correct answer. Original scores for the question totaled between 
0-200, depending on the respondents’ percentage indicating yes. Answers were 
re-scored 200 or 0 as factually appropriate - existence/non-existence of multiplex 
screening for each condition. Results: After eliminating conditions with missing 
data, 78 out of the original 84 conditions remained. 42 conditions (54%) increased 
their scores; 30 (38%) decreased. Of conditions with increasing scores, the mean 
increase was 85. Of conditions decreasing their scores, the mean decrease was 43. 
We estimate the potential change in recommendations as 4 conditions moving from 
the Core to secondary or Not Recommended and 10 moving from Secondary to Core 
status. ConClusions: As the only conditions capable of having recommendations 
altered by this correction were those roughly 200 points +/- category cutoffs and 
some ACMG rules further limited reclassification, this single correction was limited 
in its ability to alter recommendations (67% of the conditions could not change). 
Nonetheless the changes were significant (of those that could change, 50% did). As 
other questions in the survey were also questions of fact, doing a similar analysis 
for all such questions could further significantly alter the conditions recommended 
for the panel.
ment levels of these drugs in both countries. Results: Eight OD were identified. 
In Germany, G-BA decisions related to additional benefit were non-quantifiable for 
3 drugs, minor for 4 drugs, and minor in one subgroup and considerable in other 
subgroup for one drug. In France, one product was not assessed by the TC, and 
improvement in actual benefit (IAB) was rated as weak for 4 products, moderate for 
2 products and important for one product. In Germany all these drugs were 100% 
reimbursed, while in France, depending on actual benefit (AB) ratings, reimburse-
ment levels varied from non-reimbursement to 100%. At time of analysis, reim-
bursement status was granted in France for only 4 products (15% for one drug, 65% 
for one drug and 100% for 2 drugs). In Germany, OD prices were about 20% higher 
than in France before rebates, and about 20% lower after rebates. ConClusions: 
Substantial improvement for OD were less frequently acknowledged by German 
HTA than by French HTA and prices appeared to be lower in Germany than in 
France. However, price volume agreements in France might have contributed to 
hidden discounts. Access level of OD appeared higher in Germany.
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objeCtives: To understand current considerations and management of the iNHL 
and CLL disease states and the extent to which health economic outcomes data 
informs payer decision making process. Methods: A national level in-depth tel-
ephone survey of 45 payers was done in the month of November, 2013. The payer 
mix included both Commercial (n= 20) and Medicare (n= 25) payers that were either 
medical or pharmacy directors to determine clinical, economic and humanistic 
outcomes data critical for formulary and medical policy deicisons for iNHL and 
CLL. Results: US Payers are most interested in the endpoints that directly tie to 
their major cost drivers: hospitalization, re-hospitalization and emergency ser-
vices in both the disease state. Payers were split on preferring the comparative 
data of the cost-effectiveness analysis and the simple presentation of a budget 
impact model. There was no difference in payer types when it came to preference 
for any particular health economics model. Amongst the various adverse events 
related to treating iNHL and CLL, neutropenia is the most concerning adverse 
event from payer perspective, given the associated high cost of related treatments 
and hospitalizations. Payers consistently reported that the greatest unmet need 
in the iNHL and CLL today is more treatment options for relapsed and refractory 
patients, with greater response rates, increased durability of response and less 
toxicity leading to increased overall survival and progression. ConClusions: 
While in iNHL/CLL space payers admit decisions are based more on clinical evalu-
ations rather than cost drivers, payers appreciate the value of demonstrating a 
reduction in resource utilization costs as they can directly evaluate the impact of 
this data on their health plan.
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objeCtives: To identify criteria used to categorize patients with R/R CLL who are 
ineligible for cytotoxic therapy and the unmet need in these patients. Methods: 
Structured searches related to R/R CLL; performance status; comorbidities; organ 
function; and treatment patterns were performed on PubMed, Google Scholar, 
and the Cochrane databases and supplemented with hand searches of published 
literature, clinical guidelines, and online sources. Results: 440 publications were 
identified. 123 were considered relevant to the study. Patients ineligible for cyto-
toxic therapy were identified by a combination of assessments for performance 
status (using ECOG), comorbidities (CIRS), and organ function (creatinine clear-
ance (CrCl)). Unfit patients are “> 65 years with a comorbidity” (ECOG 3–4 or CIRS 
> 6 or CrCl < 70 mL/min). NCCN clinical guidelines do not refer to assessment 
scores or define unfit: the NCCN categorizes R/R CLL patients as “≥ 70 years, or 
younger with comorbidities” or “frail with significant comorbidity”. These criteria 
are not aligned with others such as slow-go (ECOG 2–4 or CIRS > 6 or CrCl < 70 mL/
min) and no-go (fatal comorbidities with very short life-expectancy). Treatment 
regimens recommended by the NCCN contain drugs contraindicated for common 
comorbidities. The RCTs for the recommended regimens did not include patients 
with contraindicated comorbidities. There is an unmet need in these patients 
for appropriate treatment. ConClusions: There exists unmet need in patients 
identified as unfit using current criteria: they can be restricted from recommended 
drugs due to contraindications for common comorbidities. Most of these patients 
also have not been included in RCTs. Criteria used to identify patients with R/R CLL 
ineligible for cytotoxic therapy are not yet standardized; standardized assessments 
are needed for uniform identification and RCT enrolment.
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objeCtives: Inappropriate use of prescription opioids costs insurers over $72 
billion annually in direct health care expenses. Prescription monitoring programs 
(PMP) are state-operated databases which allow authorized clinicians (e.g., pre-
scribers, pharmacists) to query a patient’s opioid dispensing history via a secured 
online connection, during patient care. Since the emergency department (ED) is a 
